Key terms
About BBLG
Bone Biologics Corp. operates as a medical device company. engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BBLG news
Mar 01
8:06am ET
Bone Biologics reports progress with NB1 clinical program
Jan 30
5:11pm ET
Bone Biologics files to sell common stock, warrants, no amount given
Jan 10
8:03am ET
Bone Biologics regains compliance with Nasdaq continued listing rule
Jan 05
5:18pm ET
Bone Biologics files to sell 142,384 shares of common stock for holders
Jan 05
5:18pm ET
Bone Biologics files to sell 142K shares of common stock for holders
Dec 19
7:50pm ET
Bone Biologics Corp trading halted, news pending
No recent press releases are available for BBLG
BBLG Financials
Key terms
Ad Feedback
BBLG Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BBLG Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
